Therapeutic approaches that target apoptotic pathways, such as BCL-2 inhibitors that block survival signals and TRAIL analogues that trigger death receptors, aim to reinstate the apoptotic response in resistant tumor cells. Here, BCL2 is linked to neoplasm.